Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LIVIG 10% intravenous immunoglobulin in primary immunodeficiency in South Africa
PACTR202606912106412Phase 3Not yet recruiting
- Sponsor
- National Bioproducts Institute
- Start
- Jun 2026
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in Immunogenetic disorder, sponsored by National Bioproducts Institute. Primary endpoints: Rate of serious bacterial infections, Annual rate of treatment-emergent adverse events and 4 more. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on PACTR202606912106412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606912106412.